Zomedica Pharmaceuticals logo

ZOM - Zomedica Pharmaceuticals Share Price

C$0.285   %

Last Trade - 05/02/20

Small Cap
Market Cap £225.3m
Enterprise Value £73.2m
Revenue £6.26m
Position in Universe th / 2794
Unlock ZOM Revenue
Relative Strength (%)
Volume Change (%)
Price vs... (%)
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2016 2017 2018 2019 2020 2021 2022E 2023E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 4.13 15.2 24.5
Balance Sheet
FINANCIAL BRIEF: F: For the three months ended 31 March 2022, Zomedica Corp revenues increased from $14K to $3.8M. Net loss decreased 2% to $3.9M. Revenues reflect Research, development targeting health and wellness solution segment increase from $28K to $7.5M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ZOM Revenue Unlock ZOM Revenue

Net Income

ZOM Net Income Unlock ZOM Revenue

Normalised EPS

ZOM Normalised EPS Unlock ZOM Revenue

PE Ratio Range

ZOM PE Ratio Range Unlock ZOM Revenue

Dividend Yield Range

ZOM Dividend Yield Range Unlock ZOM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2022
31st Dec 2023
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ZOM EPS Forecasts Unlock ZOM Revenue
Profile Summary

Zomedica Corp. is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. The Company is developing point-of-care diagnostic platform, which is based on miniaturized laser-based Raman spectroscopy technology and is designed to detect pathogens in companion animals. Its product portfolio includes diagnostics and therapeutic medical devices that emphasize patient health. It offers TRUFORMA is a diagnostic biosensor platform and the first five assays for the detection of thyroid disorders in dogs and cats and adrenal disorders in dogs. The TRUFORMA platform uses bulk acoustic wave (BAW) technology to provide a non-optical and fluorescence free detection system for use at the point-of-care. The TRUFORMA also offers complete control over the testing process and allow veterinarians to make clinical decisions. PulseVet platform provides treatment for musculoskeletal issues in horses and small animals.

Last Annual December 31st, 2021
Last Interim March 31st, 2022
Incorporated January 7, 2013
Public Since October 28, 2013
No. of Shareholders: n/a
No. of Employees: 47
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange TSX Venture Exchange
Shares in Issue 979,899,668
Free Float (0.0%)
Eligible for
ZOM Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Upcoming Events for ZOM
Frequently Asked Questions for Zomedica Pharmaceuticals
What is the Zomedica Pharmaceuticals share price?

As of 05/02/20, shares in Zomedica Pharmaceuticals are trading at C$0.285, giving the company a market capitalisation of £225.3m. This share price information is delayed by 15 minutes.

How has the Zomedica Pharmaceuticals share price performed this year?

Shares in Zomedica Pharmaceuticals are currently trading at C$0.285 and the price has moved by -83.24% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zomedica Pharmaceuticals price has moved by -83.76% over the past year.

What are the analyst and broker recommendations for Zomedica Pharmaceuticals?

There are no analysts currently covering Zomedica Pharmaceuticals.

When will Zomedica Pharmaceuticals next release its financial results?

Zomedica Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2023-03-31
What is the Zomedica Pharmaceuticals dividend yield?

Zomedica Pharmaceuticals does not currently pay a dividend.

Does Zomedica Pharmaceuticals pay a dividend?

Zomedica Pharmaceuticals does not currently pay a dividend.

When does Zomedica Pharmaceuticals next pay dividends?

Zomedica Pharmaceuticals does not currently pay a dividend.

How do I buy Zomedica Pharmaceuticals shares?

To buy shares in Zomedica Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zomedica Pharmaceuticals?

Shares in Zomedica Pharmaceuticals are currently trading at C$0.285, giving the company a market capitalisation of £225.3m.

Where are Zomedica Pharmaceuticals shares listed? Where are Zomedica Pharmaceuticals shares listed?

Here are the trading details for Zomedica Pharmaceuticals:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: ZOM
What kind of share is Zomedica Pharmaceuticals?

We were not able to load our ranking data for Zomedica Pharmaceuticals

Is there a Zomedica Pharmaceuticals share price forecast 2022?

We were not able to load any forecast data for Zomedica Pharmaceuticals.

How can I tell whether the Zomedica Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zomedica Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 3.75%. At the current price of C$0.285, shares in Zomedica Pharmaceuticals are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zomedica Pharmaceuticals PE Ratio?

We were not able to find PE ratio data for Zomedica Pharmaceuticals.

Who are the key directors of Zomedica Pharmaceuticals?

Zomedica Pharmaceuticals's management team is headed by:

Jeffrey Rowe - NEC
Stephanie Morley - COO
Johnny Powers - IND
Robert Cohen - DRC
Christopher MacLeod - IND
Ann Cotter - CFO
Sean Whelan - DRC
Larry Heaton - CEO
Who are the major shareholders of Zomedica Pharmaceuticals?

Here are the top five shareholders of Zomedica Pharmaceuticals based on the size of their shareholding:

Similar to ZOM
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.
{"statusCode":404,"message":"Not Found"}